A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer

M. J. Kupferminc*, J. B. Lessing, A. Amit, I. Yovel, M. P. David, M. R. Peyser

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

A randomized, prospective blind study was carried out to investigate the need for luteal phase support in patients undergoing in-vitro fertilization (IVF). One-hundred-and-fifty-six patients undergoing IVF in cycles stimulated with human menopausal gonadotrophin (HMG) and human chorionic gonadotrophin (HCG) stimulated FVF, were divided into three different groups for luteal phase treatment. Fifty-four patients received dydrogesterone three times daily (TID) beginning on the day of embryo transfer (ET). Fifty-one patients received HCG on days 3, 6 and 10 following ET. Fifty-one patients received placebo p.o. TID beginning on the day of ET. There was no difference between the groups in pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy. The data indicate that supplementation of the luteal phase may not improve the success rates of IVF-ET cycles.

Original languageEnglish
Pages (from-to)271-273
Number of pages3
JournalHuman Reproduction
Volume5
Issue number3
DOIs
StatePublished - Apr 1990

Keywords

  • Dydrogesterone
  • HCG
  • IVF
  • Luteal phase

Fingerprint

Dive into the research topics of 'A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer'. Together they form a unique fingerprint.

Cite this